(Reuters) -Sanofi plans to seek U.S. approval for its best-selling anti-inflammatory drug Dupixent to be used in the treatment of "smoker's lung", also known as COPD, after a second large trial showed ...

Regeneron Pharmaceuticals (NasdaqGS:REGN) and Sanofi secured European Commission approval for Dupixent in moderate to severe chronic spontaneous urticaria for children aged 2 to 11. The approval ...

Dupixent showed significant and clinically meaningful improvements in both esophageal distensibility as well as disease-related structural ...

Approval for children aged 2 to 11 years with CSU who remain symptomatic despite H1 antihistamine treatment based primarily on data from the ...

TARRYTOWN, N.Y. and PARIS, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Medicines Agency’s Committee for Medicinal ...

Dupixent has received regulatory approvals in one or more countries around the world for use in certain patients with atopic dermatitis, asthma, CRSwNP, EoE, prurigo nodularis, and CSU in different ...

A diagnosis of T-cell lymphoma after using Dupixent raises serious questions for patients and families. Many want clear answers about whether they may have a legal claim and what criteria determine ...

Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo in adults with BP BP is a chronic, ...

What Is It, and Why Does It Matter? Dupixent (dupilumab) is a prescription biologic medicine given as an under‑the‑skin (subcutaneous) shot that helps reduce inflammation caused by certain immune ...